Related Experiment Videos
[Scintigraphic evaluation of the ischemically damaged myocardium in patients with reduced left ventricular function.
M Schwaiger1, S Egert, F Brosius
1Nuklearmedizinische Klinik und Poliklinik, TU München Klinikum rechts der Isar.
Insights
Identifying viable heart muscle is crucial for patients with reduced heart function who may need revascularization. Thallium-201 scintigraphy with reinjection is recommended for assessing tissue viability, with PET scans for complex cases.
Area of Science:
- Cardiology
- Nuclear Medicine
- Diagnostic Imaging
Background:
- Assessing myocardial viability is critical for guiding revascularization in patients with ischemic heart disease and impaired left ventricular function.
- Advanced diagnostic techniques are essential for evaluating ischemia extent and identifying viable tissue in severe coronary artery disease.
- Positron emission tomography (PET) offers accurate scintigraphic quantification of viable myocardial tissue, but its availability is limited.
Purpose of the Study:
- To evaluate diagnostic methods for identifying viable myocardium in patients with impaired left ventricular function.
- To compare the efficacy of thallium-201 scintigraphy and positron emission tomography (PET) in assessing myocardial viability.
- To recommend a standard diagnostic procedure for tissue viability assessment.
Main Methods:
- Comparison of thallium-201 scintigraphy with reinjection protocols and positron emission tomography (PET) for myocardial viability assessment.
- Evaluation of low-dose dobutamine-echocardiography as a potential alternative for assessing contractile reserve.
- Exploration of new radiotracers and in vitro tissue analysis for understanding metabolic adaptations in ischemic heart disease.
Main Results:
- Thallium-201 scintigraphy with reinjection protocols has improved the recognition of viable tissue, reducing the diagnostic gap with PET.
- PET remains the most accurate method for scintigraphic quantification of viable myocardial tissue.
- Low-dose dobutamine-echocardiography shows potential but requires further clinical validation.
Conclusions:
- Thallium-201 scintigraphy with reinjection is recommended as the standard diagnostic procedure for assessing myocardial viability.
- PET should be considered for patients with severely depressed left ventricular function and equivocal thallium-201 findings.
- Further research with new radiotracers and tissue analysis can enhance understanding of metabolic alterations in chronic ischemic heart disease.
Abstract:
Identification of viable myocardium in patients with impaired left ventricular function, who are possible candidates for revascularization, represents an important clinical question. Modern methods of revascularization provide a therapeutic alternative to conventional pharmacological therapy even in patients with advanced ischemic heart disease. Modern diagnostic techniques make it possible to assess not only the extent of ischemia under exercise conditions, but also the presence of viable tissue in patients with severe coronary artery disease and impaired ventricular function. Currently, the most accurate methods for scintigraphic quantification of viable myocardial tissue are metabolic investigations with positron emission tomography (PET). Because of the limited availability of PET other methods like thallium-201-scintigraphy play an important clinical role. Modifications of thallium-201-scintigraphy, for example the introduction of reinjection protocols have improved the recognition of viable tissue and decreased the diagnostic difference to PET. We recommend as standard diagnostic procedure for assessment of tissue viability thallium-201-scintigraphy with reinjection. In patients with severely depressed left ventricular function and equivocal thallium-201-scintigraphy findings, PET should be considered as further diagnostic test. Low dose dobutamine-echocardiography is emerging as alternative test for evaluation of contractile reserve in dysfunctioning left ventricular segments. Its clinical role, however, remains to be determined. Besides the clinical application of these methods, newly developed radiotracers, together with PET, may provide insights into the mechanism of metabolic adaptations in patients with repeated episodes of ischemia. Furthermore, correlation of clinical data with in vitro histological and biological tissue analysis in the same patients may provide a better understanding of metabolic alterations observed in chronic ischemic heart disease.